SAM #HT9402-26-Q-9401

Pharmaceutical Agents for Military Health System Uniform Formulary – Atopy and Lung Cancer Drug Classes

This opportunity involves the Defense Health Agency (DHA) seeking pharmaceutical agents for the Military Health System's Uniform Formulary. - Government Buyer: - Defense Health Agency (DHA), Department of Defense - Managed by DHA office in Aurora, Colorado - OEMs and Vendors Mentioned: - Anzupgo - Eucrisa - Opzelura - Vtama - Zoryve - Tabrecta - Tepmetko - Products/Services Requested: - Pharmaceutical agents in two drug classes: - Atopy - Topical Agents: Anzupgo, Eucrisa, Opzelura, Vtama, Zoryve - Lung Cancer - METEX14: Tabrecta, Tepmetko - Specific product details, part numbers, and quantities are referenced in attachments (not provided) - Unique/Notable Requirements: - Products will be reviewed for clinical and cost effectiveness by the Pharmacy and Therapeutics Committee - May result in Uniform Formulary Blanket Purchase Agreements (UF BPA) and/or Uniform Formulary Additional Discount Program Agreements (UF ADP) - Inclusion in the formulary is not guaranteed and depends on committee decisions

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed:

a. Atopy - Topical Agents

Anzupgo  Eucrisa  Opzelura Vtama Zoryve

b. Lung Cancer - METEX14

Tabrecta Tepmetko

The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Additional Links:https://health.mil/PandT

View original listing